EyePoint Pharmaceuticals (EYPT) Financials: History & Chart

EyePoint Pharmaceuticals, Inc.(EYPT)

Biotechnology · Watertown, MA

$3.24+0.08 (+2.70%)

Delayed quote: Oct 6, 2026, 11:40 AM EDT

About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.

Watertown, MA

214 employees

www.eyepoint.bio

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jay S. Duker

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	2.79M	507K	696K	620K	966K	5.33M	24.45M	11.59M	10.52M
Cost of Goods Sold	1.62M	0.00	528K	375K	721K	165K	805K	816K	736K
Gross Profit	1.17M	507K	168K	245K	245K	5.17M	23.65M	10.77M	9.79M
Gross Profit Margin	41.8%	100.0%	24.1%	39.5%	25.4%	96.9%	96.7%	93.0%	93.0%
Total Operating Expenses	318.14M	97.89M	87.39M	70.59M	62.27M	67.39M	72.48M	56.01M	42.54M
Research & Development	262.73M	83.61M	72.15M	59.21M	47.75M	55.50M	58.57M	43.37M	29.54M
Selling, General & Administrative	55.41M	14.27M	15.25M	11.38M	14.52M	11.90M	13.91M	12.64M	12.99M
Operating Income (EBIT)	-316.98M	-97.38M	-87.23M	-70.34M	-62.02M	-62.23M	-48.84M	-45.24M	-32.75M
Operating Margin	-11365.2%	-19207.1%	-12532.5%	-11346.0%	-6420.8%	-1166.8%	-199.7%	-390.4%	-311.2%
Income Before Tax (EBT)	-306.51M	-94.47M	-84.88M	-67.42M	-59.73M	-59.33M	-45.20M	-41.31M	-29.36M
Interest Income	10.47M	2.91M	2.34M	2.92M	2.29M	2.89M	3.64M	3.94M	3.39M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	14K	N/A
Other Income/Expense	10.47M	2.91M	2.34M	2.92M	2.29M	2.89M	3.64M	3.93M	3.39M
Net Income	-306.64M	-94.47M	-84.83M	-67.61M	-59.73M	-59.43M	-45.20M	-41.40M	-29.36M
Income Tax Expense	-136K	0.00	50K	-186K	0.00	93K	0.00	90K	0.00
Net Profit Margin	-10994.7%	-18633.1%	-12188.5%	-10904.7%	-6183.4%	-1114.3%	-184.8%	-357.3%	-279.0%
EBITDA	-313.74M	-96.05M	-86.59M	-69.65M	-61.45M	-61.69M	-48.34M	-44.77M	-32.34M
EBITDA Margin	-11249.2%	-18945.6%	-12441.1%	-11233.4%	-6361.2%	-1156.7%	-197.7%	-386.4%	-307.3%
Depreciation & Amortization	3.24M	1.33M	636K	698K	576K	538K	497K	467K	408K
EPS Basic	-3.74	-1.09	-0.99	-0.81	-0.85	-0.85	-0.65	-0.64	-0.54
EPS Diluted	-3.74	-1.09	-0.99	-0.81	-0.85	-0.85	-0.65	-0.64	-0.54
Weighted Average Basic Shares	86.54M	86.54M	86.00M	83.03M	70.17M	69.93M	69.77M	64.56M	54.45M
Weighted Average Diluted Shares	86.54M	86.54M	86.00M	83.03M	70.17M	69.93M	69.77M	64.56M	54.45M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	06/30/2018
Revenue	31.37M	43.27M	46.02M	41.40M	36.94M	34.44M	20.36M	5.86M
Cost of Goods Sold	2.07M	3.71M	4.63M	8.33M	8.18M	5.82M	2.69M	18.50M
Gross Profit	29.30M	39.56M	41.39M	33.08M	28.76M	28.61M	17.68M	-13.93M
Gross Profit Margin	93.4%	91.4%	89.9%	79.9%	77.9%	83.1%	86.8%	-237.9%
Total Operating Expenses	272.74M	185.41M	116.45M	132.72M	84.04M	65.90M	65.54M	52.32M
Research & Development	221.04M	132.93M	64.66M	49.64M	28.50M	17.42M	15.37M	20.82M
Selling, General & Administrative	51.70M	52.49M	51.79M	60.32M	53.08M	46.02M	47.71M	31.50M
Operating Income (EBIT)	-243.43M	-145.85M	-75.07M	-99.64M	-55.28M	-37.29M	-47.86M	-49.12M
Operating Margin	-776.0%	-337.1%	-163.1%	-240.6%	-149.6%	-108.3%	-235.0%	-838.8%
Income Before Tax (EBT)	-231.68M	-130.78M	-70.71M	-102.25M	-58.42M	-45.39M	-56.79M	-89.44M
Interest Income	11.75M	15.09M	6.95M	2.13M	292K	58K	1.05M	101K
Interest Expense	N/A	14K	1.25M	3.19M	5.50M	7.26M	6.18M	720K
Other Income/Expense	11.75M	15.07M	4.36M	-2.62M	-3.14M	-8.10M	-8.93M	-40.32M
Net Income	-231.96M	-130.87M	-70.80M	-102.25M	-58.42M	-45.39M	-56.79M	-53.17M
Income Tax Expense	279K	90K	83K	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-739.4%	-302.4%	-153.8%	-247.0%	-158.1%	-131.8%	-278.9%	-908.0%
EBITDA	-241.13M	-144.31M	-74.60M	-97.19M	-52.51M	-34.64M	-45.26M	-46.47M
EBITDA Margin	-768.6%	-333.5%	-162.1%	-234.7%	-142.1%	-100.6%	-222.2%	-793.5%
Depreciation & Amortization	2.31M	1.54M	464K	2.45M	2.77M	2.65M	2.60M	2.65M
EPS Basic	-3.17	-2.32	-1.82	-2.74	-2.03	-3.54	-5.44	-12.71
EPS Diluted	-3.17	-2.32	-1.82	-2.74	-2.03	-3.54	-5.44	-11.50
Weighted Average Basic Shares	73.25M	56.30M	38.90M	37.32M	28.76M	12.84M	10.43M	4.62M
Weighted Average Diluted Shares	73.25M	56.30M	38.90M	37.32M	28.76M	12.84M	10.43M	4.62M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.